While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Tirzepatide works by targeting multiple pathways ... not interfere with the active ingredients while providing necessary structure and consistency to the product. By maintaining a clean label ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a review in the Journal of Endocrinology. Credit not just the weight loss but ...

Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1 ... Newer GLP-1 receptor agonists like tirzepatide, (which combines a GLP-1 mimic with the mimic ...

Detailed price information for Goldman Sachs Group (GS-N) from The Globe and Mail including charting and trades.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Good news: The risk is small. GLP-1s affect cells in a tiny V-shaped structure in your brain stem. This zone is a chemoreceptor—a spot that makes you feel like hurling when it meets something it ...